ly 293111 has been researched along with calcimycin in 1 studies
| Studies (ly 293111) | Trials (ly 293111) | Recent Studies (post-2010) (ly 293111) | Studies (calcimycin) | Trials (calcimycin) | Recent Studies (post-2010) (calcimycin) |
|---|---|---|---|---|---|
| 38 | 9 | 6 | 11,946 | 40 | 444 |
| Protein | Taxonomy | ly 293111 (IC50) | calcimycin (IC50) |
|---|---|---|---|
| XBP1 | Homo sapiens (human) | 1.41 | |
| DNA damage-inducible transcript 3 protein | Mus musculus (house mouse) | 0.16 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendele, AM; Cockerham, SL; Froelich, LL; Jackson, WT; Sawyer, JS; Silbaugh, SA; Sofia, MJ; Spaethe, SM; Stengel, PW | 1 |
1 other study(ies) available for ly 293111 and calcimycin
| Article | Year |
|---|---|
Pharmacologic actions of the second generation leukotriene B4 receptor antagonist LY29311: in vivo pulmonary studies.
Topics: Airway Obstruction; Animals; Benzoates; Benzopyrans; Bronchoalveolar Lavage Fluid; Calcimycin; Chemotaxis, Leukocyte; Dinoprostone; Granulocytes; Guinea Pigs; Inflammation; Leukotriene Antagonists; Leukotriene B4; Lung; Male; Receptors, Leukotriene B4; Thromboxane B2 | 2000 |